A5065449257- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Pharmaceutical studies and practices
- Esophageal Cancer Research and Treatment
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Venous Thromboembolism Diagnosis and Management
- Health Systems, Economic Evaluations, Quality of Life
- Gastroesophageal reflux and treatments
- Colorectal Cancer Screening and Detection
- Bariatric Surgery and Outcomes
- Tracheal and airway disorders
- IL-33, ST2, and ILC Pathways
- Pregnancy and Medication Impact
- Atrial Fibrillation Management and Outcomes
- Antiplatelet Therapy and Cardiovascular Diseases
- Clostridium difficile and Clostridium perfringens research
- Genomics and Rare Diseases
- Metastasis and carcinoma case studies
- Genetic Associations and Epidemiology
- Gastrointestinal Bleeding Diagnosis and Treatment
Rashid Hospital
2016-2025
Dubai Health Authority
2016-2024
Dubai Medical College
2024
Inflammatory bowel disease (IBD) is emerging in the newly industrialized countries of South Asia, South-East and Middle East, yet epidemiological data are scarce.We performed a cross-sectional study IBD demographics, phenotype, treatment across 38 centers 15 East. Intergroup comparisons included gross national income (GNI) per capita.Among 10 400 patients, ulcerative colitis (UC) was twice as common Crohn's (CD), with male predominance (UC 6678, CD 3495, unclassified 227, 58% male). Peak age...
Objectives 5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy. Methods A decision tree followed 10 000 newly diagnosed patients with mild-to-moderately active UC through induction and 1 year maintenance treatment. Optimised (maximising dose use combined oral rectal therapy before escalation) was compared standard (standard doses without optimisation)....
As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. Addressing various challenges in clinical management of inflammatory bowel disease (IBD) remains crucial. To shed light on physicians' current knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption-whether initiating a biosimilar, transitioning from an or switching between (including multiple switches reverse switching)-a...
ABSTRACT Background Many patients diagnosed with gastro‐oesophageal reflux disease (GERD) have persistent symptoms despite proton pump inhibitor (PPI) therapy. Aims The aim of this consensus is to provide evidence‐based statements guide clinicians caring for refractory reflux‐like (rRLS) or GERD. Methods This was developed by the International Working Group Classification Oesophagitis. steering committee specific PICO questions pertaining management PPI rRLS. Methodologists conducted...
Background: Inflammatory bowel diseases (IBD) are chronic, relapsing-remitting inflammatory conditions with a substantial negative impact on health-related quality of life and work productivity. Treatment IBD has been revolutionized by the advent biologic therapies, initially anti-TNF agents more recently multiple alternatives targets, yet under development. Objectives: Approximatively one third patients do not respond to therapy importantly significant proportion experiences partial...
While biologic originators’ patents are expiring, biosimilars emerging to take their place, offering significant cost savings healthcare systems. Many challenges still need be addressed in the clinical practice of inflammatory bowel disease (IBD). A global survey was organized highlight physicians’ current knowledge and beliefs gain insight about practical management remaining concerns obstacles associated with starting a biosimilar, switching from an originator or one biosimilar another...
Interventional clinical trials in ASUC are characterised by substantial heterogeneity due to a lack of consensus several key areas trial design - this impedes research efforts identify novel therapies. The objective initiative was achieve the first and provide clear position statements on design. A modified Delphi approach employed with panel twenty clinicians international representation expertise delivery. Agreement defined as at least 75% participants voting 'agree' each statement. In...
To understand current thinking and clinical decision-making in the treatment management of patients with mild-to-moderate ulcerative colitis (UC).This multinational, survey-based study was conducted 2021. Two meetings were held, involving 11 IBD specialists, that used a series questions discussion to identify all factors possibly related UC. The importance identified assessed using an online questionnaire covering three scenarios - active disease, remission patient empowerment. Each factor...